Alzamend Neuro Inc

NASDAQ:ALZN   3:59:42 PM EDT
0.88
-0.05 (-5.18%)
Products, Regulatory

Alzamend Neuro Announces Full Data Set From Phase 1 First-In-Human Clinical Trial For Al001 Treatment Of Dementia Related To Alzheimer's

Published: 03/28/2022 13:01 GMT
Alzamend Neuro Inc (ALZN) - Alzamend Neuro Announces Full Data Set From Phase 1 First-in-human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer's.
Alzamend Neuro Inc - Results Show That Shapes of Lithium Plasma Concentration Versus Time Curves Are Similar to Marketed Product.
Alzamend Neuro Inc - Al001 Salicylate Plasma Concentrations Were Observed to Be Well Tolerated and Consistently Within Safe Limits.
Alzamend Neuro Inc - Safety Profiles of Both Al001 and Marketed Lithium Carbonate Capsule Were Benign.
Alzamend Neuro Inc - Look Forward to Initiating a Phase 2 Multiple Ascending Dose Study Involving Alzheimer's Patients in Q2 of 2022.
Alzamend Neuro Inc - Look Forward to Pursuing Ind Applications With U.S. FDA During 2022 for Bipolar Disorder, Depression, and Ptsd Indications.